DocGo Q3 adjusted EBITDA beats analyst expectations on business lines restructuring
DCGO•DocGo reported a Q3 adjusted EBITDA loss of $3.2 million, narrower than the $4.43 million analyst consensus, while revenue of $73.4 million missed the $77.19 million estimate. The company lowered its 2026 revenue outlook to $300 million from $305 million to $310 million and maintained adjusted EBITDA guidance of a $17 million to $22 million loss.
1. Quarterly results
DocGo said Q3 revenue rose year over year to $73.4 million but fell short of the $77.19 million analyst consensus. Its net loss was $18.29 million, while its adjusted EBITDA loss narrowed to $3.2 million, beating the $4.43 million expected loss.
2. Outlook and margins
The company lowered its full-year 2026 revenue outlook to $300 million from $305 million to $310 million and maintained its adjusted EBITDA loss guidance of $17 million to $22 million. Gross margin improved 280 basis points from Q2, which DocGo attributed to profitability initiatives, including cost controls, and restructuring or eliminating unprofitable business lines. The company said it expects improved margins and increased volumes as patient outreach ramps up, and reported record volumes in medical transportation, mobile phlebotomy and remote monitoring.
